These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 21617573)

  • 1. Immunogenicity and safety of an inactivated hepatitis A vaccine when coadministered with measles-mumps-rubella and varicella vaccines in children less than 2 years of age.
    Rinderknecht S; Michaels MG; Blatter M; Gaglani M; Andrews W; Abughali N; Chandreshekaran V; Trofa AF
    Pediatr Infect Dis J; 2011 Oct; 30(10):e179-85. PubMed ID: 21617573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and safety of two tetravalent (measles, mumps, rubella, varicella) vaccines coadministered with hepatitis a and pneumococcal conjugate vaccines to children twelve to fourteen months of age.
    Blatter MM; Klein NP; Shepard JS; Leonardi M; Shapiro S; Schear M; Mufson MA; Martin JM; Varman M; Grogg S; London A; Cambron P; Douha M; Nicholson O; da Costa C; Innis BL
    Pediatr Infect Dis J; 2012 Aug; 31(8):e133-40. PubMed ID: 22622699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and safety of measles-mumps-rubella, varicella and Haemophilus influenzae type b vaccines administered concurrently with a fourth dose of heptavalent pneumococcal conjugate vaccine compared with the vaccines administered without heptavalent pneumococcal conjugate vaccine.
    Black SB; Cimino CO; Hansen J; Lewis E; Ray P; Corsaro B; Graepel J; Laufer D
    Pediatr Infect Dis J; 2006 Apr; 25(4):306-11. PubMed ID: 16567981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age.
    Goh P; Lim FS; Han HH; Willems P
    Infection; 2007 Oct; 35(5):326-33. PubMed ID: 17710370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
    Vesikari T; Baer M; Willems P
    Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life.
    Schuster V; Otto W; Maurer L; Tcherepnine P; Pfletschinger U; Kindler K; Soemantri P; Walther U; Macholdt U; Douha M; Pierson P; Willems P
    Pediatr Infect Dis J; 2008 Aug; 27(8):724-30. PubMed ID: 18600190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age.
    Nolan T; Bernstein DI; Block SL; Hilty M; Keyserling HL; Marchant C; Marshall H; Richmond P; Yogev R; Cordova J; Cho I; Mendelman PM;
    Pediatrics; 2008 Mar; 121(3):508-16. PubMed ID: 18310199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine.
    Gillet Y; Steri GC; Behre U; Arsène JP; Lanse X; Helm K; Esposito S; Meister N; Desole MG; Douha M; Willems P
    Vaccine; 2009 Jan; 27(3):446-53. PubMed ID: 19007835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age.
    Halperin SA; Ferrera G; Scheifele D; Predy G; Stella G; Cuccia M; Douha M; Willems P
    Vaccine; 2009 May; 27(20):2701-6. PubMed ID: 19428882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An open-label, randomized, multi-center study of the immunogenicity and safety of DTaP-IPV (Kinrix™) co-administered with MMR vaccine with or without varicella vaccine in healthy pre-school age children.
    Klein NP; Weston WM; Kuriyakose S; Kolhe D; Howe B; Friedland LR; Van Der Meeren O
    Vaccine; 2012 Jan; 30(3):668-74. PubMed ID: 22064267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and safety of an inactivated hepatitis A vaccine administered concomitantly with diphtheria-tetanus-acellular pertussis and haemophilus influenzae type B vaccines to children less than 2 years of age.
    Nolan T; Bernstein H; Blatter MM; Bromberg K; Guerra F; Kennedy W; Pichichero M; Senders SD; Trofa A; Collard A; Sullivan DC; Descamps D
    Pediatrics; 2006 Sep; 118(3):e602-9. PubMed ID: 16950952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concomitant administration of a virosome-adjuvanted hepatitis a vaccine with routine childhood vaccines at age twelve to fifteen months: a randomized controlled trial.
    Dagan R; Amir J; Livni G; Greenberg D; Abu-Abed J; Guy L; Ashkenazi S; Foresner G; Tewald F; Schätzl HM; Hoffmann D; Ibanez R; Herzog C
    Pediatr Infect Dis J; 2007 Sep; 26(9):787-93. PubMed ID: 17721372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and safety of an inactivated hepatitis A vaccine when coadministered with Diphtheria-tetanus-acellular pertussis and haemophilus influenzae type B vaccines in children 15 months of age.
    Trofa AF; Klein NP; Paul IM; Michaels MG; Goessler M; Chandrasekaran V; Blatter M
    Pediatr Infect Dis J; 2011 Sep; 30(9):e164-9. PubMed ID: 21494175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, tolerability and immunogenicity of VAQTA given concomitantly versus nonconcomitantly with other pediatric vaccines in healthy 12-month-old children.
    Guerra FA; Gress J; Werzberger A; Reisinger K; Walter E; Lakkis H; Grosso AD; Welebob C; Kuter BJ;
    Pediatr Infect Dis J; 2006 Oct; 25(10):912-9. PubMed ID: 17006287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Marin M; Broder KR; Temte JL; Snider DE; Seward JF;
    MMWR Recomm Rep; 2010 May; 59(RR-3):1-12. PubMed ID: 20448530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.
    Lieberman JM; Williams WR; Miller JM; Black S; Shinefield H; Henderson F; Marchant CD; Werzberger A; Halperin S; Hartzel J; Klopfer S; Schödel F; Kuter BJ;
    Pediatr Infect Dis J; 2006 Jul; 25(7):615-22. PubMed ID: 16804432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and safety of a varicella vaccine, Okavax, and a trivalent measles, mumps and rubella vaccine, MMR-II, administered concomitantly in healthy Filipino children aged 12-24 months.
    Gatchalian S; Leboulleux D; Desauziers E; Bermal N; Borja-Tabora C
    Southeast Asian J Trop Med Public Health; 2003 Sep; 34(3):589-97. PubMed ID: 15115135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of a measles, mumps, rubella and varicella vaccine given with combined Haemophilus influenzae type b conjugate/hepatitis B vaccines and combined diphtheria-tetanus-acellular pertussis vaccines.
    Shinefield H; Black S; Thear M; Coury D; Reisinger K; Rothstein E; Xu J; Hartzel J; Evans B; Digilio L; Schödel F; Brown ML; Kuter B;
    Pediatr Infect Dis J; 2006 Apr; 25(4):287-92. PubMed ID: 16567978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety of a two-dose regimen of a combined measles, mumps, rubella and varicella live vaccine (ProQuad(®)) in infants from 9 months of age.
    Vesikari T; Becker T; Gajdos V; Fiquet A; Thomas S; Richard P; Baudin M
    Vaccine; 2012 Apr; 30(20):3082-9. PubMed ID: 22406278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.
    Knuf M; Habermehl P; Zepp F; Mannhardt W; Kuttnig M; Muttonen P; Prieler A; Maurer H; Bisanz H; Tornieporth N; Descamps D; Willems P
    Pediatr Infect Dis J; 2006 Jan; 25(1):12-8. PubMed ID: 16395096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.